Navigation Links
China-Biotics, Inc. Announces Conference Call to Discuss First Quarter Fiscal 2010 Financial Results
Date:8/14/2009

SHANGHAI, Aug. 14 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics," "the Company"), a leading Chinese firm specializing in the research, development, manufacture, marketing and distribution of probiotics dietary supplements, today announced it will host a conference call at 10:00 a.m. EDT on Monday, August 17, 2009, to discuss the Company's financial results for the first quarter of its 2010 fiscal year.

To participate in the event by telephone, please dial 877-485-3104 five to 10 minutes prior to the start time (to allow time for registration) and reference the conference ID 330544. International callers should dial 201-689-8579.

A digital replay of the call will be available on Monday, August 17 at approximately 11:00 a.m. EDT through Monday, August 24 at midnight EDT. To listen to the replay, dial 877-660-6853 and enter the conference ID number 330544. International callers should dial 201-612-7415 and enter the same conference ID number.

The conference call will also be webcast live over the Internet and can be accessed by all interested parties at the company's Web site, http://www.chn-biotics.com .

To monitor the live webcast, please go to this web site at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. An audio replay of the event will be archived on China-Biotics' Web site at http://www.chn-biotics.com/ for 90 days.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

    For further information, please contact:

    China-Biotics, Inc.
     Lewis Fan, CFO
     Email: lewisfan@chn-biotics.com
     Web:  http://www.chn-biotics.com

    CCG Investor Relations
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. China-Biotics, Inc. Reports Third Quarter 2009 Financial Results
2. China-Biotics, Inc. Announces Conference Call to Discuss Third Quarter 2009 Financial Results
3. China-Biotics, Inc. Signs Agreements With Four Additional Food Manufacturers
4. China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results
5. China-Biotics, Inc. Sees No Impact on Its Business From Dairy Products Safety Concerns
6. China-Biotics, Inc. Expands Retail Network to 60 Shining Retail Centers
7. Purple Communications(TM) Announces Second Quarter 2009 Results
8. Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults
9. Centrix Pharmaceutical Announces Clofera(TM), a Unique Antitussive and Nasal Decongestant for the Temporary Relief of Cough and Nasal Congestion
10. TrinityCare Senior Living, Inc. Announces Second Quarter Operating Results
11. Pregis Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging ... Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, ...
(Date:12/5/2016)... ... 2016 , ... A newly released study has found that ... accuracy of placing precordial electrodes with little cognitive effort and a high degree ... studies have shown that single electrode misplacement is one of the single largest ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 03, 2016 , ... While James Earl Jones is known for myriad roles ... show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a very ... in large part due to early detection. Like any other disease, treatments have a ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® was ... Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and ... Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec 5, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... , , ... reach 17.27 billion by 2021, at a CAGR of 5.3% from 2016 ... growing number of obesity cases, increasing government spending on healthcare, and rising ...
(Date:12/5/2016)... PharmaBoardroom today releases its new 70 page Switzerland Healthcare & Life ... , , ... stakeholders crucial insight into Switzerland ; a country located ... of the world,s most important international health institutions as well as two ... number one ranking globally in terms of ease of doing business and ...
(Date:12/4/2016)... , Dec. 4, 2016 Blueprint ... in discovering and developing targeted kinase medicines for ... from its ongoing Phase 1 trial evaluating BLU-285, ... with advanced systemic mastocytosis (SM). Blueprint Medicines is ... of D816V mutant KIT. Approximately 90 to 95 ...
Breaking Medicine Technology: